The clinical and functional significance of c-Met in breast cancer: a reviewReport as inadecuate




The clinical and functional significance of c-Met in breast cancer: a review - Download this document for free, or read online. Document in PDF available to download.

Breast Cancer Research

, 17:52

First Online: 08 April 2015Received: 25 July 2014Accepted: 05 March 2015DOI: 10.1186-s13058-015-0547-6

Cite this article as: Ho-Yen, C.M., Jones, J.L.
& Kermorgant, S.
Breast Cancer Res 2015 17: 52.
doi:10.1186-s13058-015-0547-6

Abstract

c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor HGF, activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression.
Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor is regarded as a novel therapeutic target.
In breast cancer there is a need to develop new treatments, particularly for the aggressive subtypes such as triple-negative and basal-like cancer, which currently lack targeted therapy.
Over the last two decades, much has been learnt about the functional role of c-Met signalling in different models of breast development and cancer.
This work has been complemented by clinical studies, establishing the prognostic significance of c-Met in tissue samples of breast cancer.
While the clinical trials of anti-c-Met therapy in advanced breast cancer progress, there is a need to review the existing evidence so that the potential of these treatments can be better appreciated.
The aim of this article is to examine the role of HGF-c-Met signalling in in vitro and in vivo models of breast cancer, to describe the mechanisms of aberrant c-Met signalling in human tissues, and to give a brief overview of the anti-c-Met therapies currently being evaluated in breast cancer patients.
We will show that the HGF-c-Met pathway is associated with breast cancer progression and suggest that there is a firm basis for continued development of anti-c-Met treatment, particularly for patients with basal-like and triple-negative breast cancer.

AbbreviationsBCLBreast cancer cell line

BLBasal-like

EGFREpidermal growth factor receptor

HGFHepatocyte growth factor

IHCImmunohistochemistry

RTKReceptor tyrosine kinase

TNTriple negative

Download fulltext PDF



Author: Colan M Ho-Yen - J Louise Jones - Stephanie Kermorgant

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents